A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.